Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles

被引:12
作者
Balayla, Jacques [1 ]
Tulandi, Togas [1 ]
Buckett, William [1 ]
Holzer, Hananel [1 ,2 ]
Steiner, Naama [1 ]
Shrem, Guy [1 ]
Volodarsky-Perel, Alexander [1 ,3 ]
机构
[1] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada
[2] Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel
[3] Jewish Gen Hosp, Lady Davis Res Inst, 3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada
关键词
Triple-negative breast cancer; Fertility preservation; Number of oocytes; Estrogen receptor; Progesterone receptor; EMBRYO-TRANSFER; LIVE BIRTH; WOMEN; ESTROGEN; TAMOXIFEN; ASSOCIATION; EXPRESSION; MUTATIONS; FEATURES; IMPACT;
D O I
10.1007/s10815-020-01730-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To evaluate fertility preservation outcomes in breast cancer women with different hormonal receptor profiles before oncological treatment. Methods The study population included women with a diagnosis of breast cancer who underwent fertility preservation from 2009 until 2018 at a university-affiliated tertiary hospital. Stimulation parameters and fertility preservation outcomes were compared among the following receptor-specific profile groups: (1) estrogen receptor positive (ER+) versus estrogen receptor negative (ER-), (2) triple-negative breast cancer (TNBC) versus estrogen and progesterone receptor positive (ER+/PR+), and (3) TNBC versus non-TNBC. Primary outcome was the total number of mature oocytes. Secondary outcomes included the number of retrieved oocytes, the peak estradiol level, and the number of follicles > 14 mm on the final oocyte maturation trigger day. Results A total of 155 cycles were included in the final analysis. These were divided into the exposure groups of ER+ (n = 97), ER- (n = 58), ER+/PR+ (n = 85), TNBC (n = 57), and non-TNBC (n = 98). Cycle outcomes revealed similar number of retrieved oocytes and follicles > 14 mm on the trigger day. Women with TNBC had significantly lower number of mature oocytes compared with those with ER + PR+ (7 (5-11) versus 9 (7-15); p = 0.02) and non-TNBC (7 (5-11) versus 9 (7-16); p = 0.01) status. Triple-negative breast cancer profile was associated with a significant reduction in the chance of developing over 10 mature oocytes (OR 0.41; 95% CI 0.19-0.92). Conclusion Among the different hormonal receptor profiles in breast cancer, the TNBC subtype has a negative effect on fertility preservation outcomes.
引用
收藏
页码:913 / 921
页数:9
相关论文
共 50 条
  • [41] Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation
    Moravek, Molly B.
    Confino, Rafael
    Lawson, Angela K.
    Smith, Kristin N.
    Kazer, Ralph R.
    Klock, Susan C.
    Gradishar, William J.
    Jeruss, Jacqueline S.
    Pavone, Mary Ellen
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 429 - 437
  • [42] Fertility preservation in breast cancer patients
    Tadahiko Shien
    Mikiya Nakatsuka
    Hiroyoshi Doihara
    Breast Cancer, 2014, 21 : 651 - 655
  • [43] Controlled ovarian stimulation in patients with breast cancer: Measures for protection of fertility
    Felberbaum R.
    Küpker W.
    Diedrich K.
    Der Gynäkologe, 2018, 51 (11): : 937 - 945
  • [44] Fertility preservation in breast cancer patients
    Shien, Tadahiko
    Nakatsuka, Mikiya
    Doihara, Hiroyoshi
    BREAST CANCER, 2014, 21 (06) : 651 - 655
  • [45] Surgical therapeutic management for the preservation of fertility in patients with cervical, endometrial, and ovarian cancer
    Villatoro, A. Redondo
    Lopez, M. Moreno
    Garrido, M. Pantoja
    CLINICA E INVESTIGACION EN GINECOLOGIA Y OBSTETRICIA, 2021, 48 (03):
  • [46] Cryopreservation of ovarian tissue for fertility preservation in breast cancer patients: time to stop?
    Macklon, Kirsten Tryde
    De Vos, Michel
    REPRODUCTIVE BIOMEDICINE ONLINE, 2024, 49 (01)
  • [47] Patients undergoing elective and oncofertility preservation respond similarly to controlled ovarian stimulation for fertility preservation
    Frare Kira, Ariane Tieko
    Hentschke, Marta Ribeiro
    de Vasconcelos, Natalia Fontoura
    Colombo, Talita
    Trindade, Vanessa Devens
    Petracco, Alvaro
    Pinheiro da Costa, Bartira Ercilia
    Badalotti, Mariangela
    JORNAL BRASILEIRO DE REPRODUCAO ASSISTIDA, 2022, 26 (03): : 407 - 411
  • [48] Ovarian response to stimulation for fertility preservation in women with hematologic cancer
    Brun, Tiffany
    Dion, Ludivine
    Jaillard, Sylvie
    Bales, Diane
    Domin, Mathilde
    Lavoue, Vincent
    Leveque, Jean
    Houot, Roch
    Duros, Solene
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2021, 50 (05)
  • [49] Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study
    Goldrat, Oranite
    De Cooman, Manon
    Mailliez, Audrey
    Delbaere, Anne
    D'Orazio, Emmanuelle
    Demeestere, Isabelle
    Decanter, Christine
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 134 - 141
  • [50] The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women
    Checa Vizcaino, Miguel A.
    Robles Corchado, Anna
    Cuadri, Margalida E. Sastre I.
    Gonzalez Comadran, Mireia
    Brassesco, Mario
    Carreras, Ramon
    REPRODUCTIVE BIOMEDICINE ONLINE, 2012, 24 (06) : 606 - 610